Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 200 av 201 resultater
Tid
Selskap
Tittel
Sektor
Kategori
24 Jan 2022
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics annonce le maintien de l’amélioration cliniquement significative de la vision, 4 ans après une seule injection de la thérapie génique LUMEVOQ®
20103010 Biotechnology
Other subject
24 Jan 2022
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
20103010 Biotechnology
Other subject
18 Jan 2022
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics publie sa situation nette de trésorerie au 31 décembre 2021 et fait un point sur ses activités
20103010 Biotechnology
Other subject
18 Jan 2022
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update
20103010 Biotechnology
Other subject
14 Dec 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics confirme le maintien de l’efficacité et de la tolérance d’une injection bilatérale de LUMEVOQ® après 2 ans dans l’essai de phase III REFLECT
20103010 Biotechnology
Other subject
14 Dec 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
20103010 Biotechnology
Other subject
01 Dec 2021
18:00 CET
GENSIGHT BIOLOGICS
GENSIGHT BIOLOGICS : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
01 Dec 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
20103010 Biotechnology
Other subject
01 Dec 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics annonce la publication d’une étude rapportant la présence de vecteur ADN de LUMEVOQ® dans les yeux controlatéraux après injection unilatérale chez des primates non humains
20103010 Biotechnology
Other subject
30 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
20103010 Biotechnology
Other subject
30 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics tiendra un webcast avec un leader d’opinion sur les résultats des patients traités bilatéralement avec LUMEVOQ® en usage compassionnel aux États-Unis
20103010 Biotechnology
Other subject
23 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics invite Julien Secheyron, « Patient N°15 » de la 1ère étude clinique de LUMEVOQ®, à venir présenter son livre « Vous ne verrez plus »
20103010 Biotechnology
Meetings / events
22 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics tiendra un webcast avec un leader d’opinion sur les résultats des patients traités bilatéralement avec LUMEVOQ® en usage compassionnel aux États-Unis
20103010 Biotechnology
Other subject
22 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
20103010 Biotechnology
Other subject
17 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
20103010 Biotechnology
Other subject
17 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics rapporte un second cas de récupération visuelle chez une patiente traitée avec la thérapie optogénétique GS030
20103010 Biotechnology
Other subject
15 Nov 2021
18:00 CET
GENSIGHT BIOLOGICS
GENSIGHT BIOLOGICS : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
15 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022
20103010 Biotechnology
Other subject
15 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics annonce la prolongation par l’EMA de la période de « clock-stop » à 120 jours du dossier réglementaire de LUMEVOQ® ; la procédure d'examen reprendra désormais en avril 2022
20103010 Biotechnology
Other subject
12 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
20103010 Biotechnology
Meetings / events
12 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics présentera de nouveaux résultats cliniques des thérapies géniques LUMEVOQ® et GS030 au Congrès 2021 de l’American Academy of Ophthalmology
20103010 Biotechnology
Meetings / events
10 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Reports Cash Position as of September 30, 2021 and Provides Operational Update
20103010 Biotechnology
Other subject
10 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics publie sa situation nette de trésorerie au 30 septembre 2021 et fait un point sur ses activités
20103010 Biotechnology
Other subject
04 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics fait le point sur les activités de production nécessaires à la demande d’Autorisation de Mise sur le Marché de LUMEVOQ®
20103010 Biotechnology
Other subject
04 Nov 2021
07:30 CET
GENSIGHT BIOLOGICS
GenSight Biologics Provides Update on Manufacturing Timeline Needed for LUMEVOQ® Regulatory Filing
20103010 Biotechnology
Other subject
12 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce l’octroi par la FDA de la désignation Fast Track pour GS030 comme traitement optogénétique de la rétinopathie pigmentaire
20103010 Biotechnology
Other subject
12 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
20103010 Biotechnology
Other subject
06 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce la publication d’une revue des essais de thérapie génique pour la NOHL dans International Ophthalmology Clinics
20103010 Biotechnology
Other subject
06 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
20103010 Biotechnology
Other subject
04 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
Les résultats cliniques des thérapies géniques LUMEVOQ®et GS030 de GenSight Biologics seront présentés aux congrès 2021 de l’ASRS et de l’ESGCT, ainsi qu’à plusieurs conférences en octobre
20103010 Biotechnology
Meetings / events
04 Oct 2021
07:30 CEST
GENSIGHT BIOLOGICS
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October
20103010 Biotechnology
Meetings / events
01 Oct 2021
14:06 CEST
GENSIGHT BIOLOGICS
GENSIGHT BIOLOGICS : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
15 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce les conclusions positives du Data Safety Monitoring Board (DSMB) de l’étude clinique de Phase I/II PIONEER de GS030 comme traitement optogénétique de la rétinopathie pigmentaire
20103010 Biotechnology
Products and services
15 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
20103010 Biotechnology
Products and services
09 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce la publication d’une analyse des paramètres visuels chez les sujets atteints de ND4-NOHL avant traitement avec LUMEVOQ® dans les études de Phase III
20103010 Biotechnology
Other subject
09 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
20103010 Biotechnology
Other subject
06 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
La MHRA accorde le statut de Promising Innovative Medicine au Royaume-Uni à la thérapie génique LUMEVOQ®de GenSight Biologics
20103010 Biotechnology
Products and services
06 Sep 2021
07:30 CEST
GENSIGHT BIOLOGICS
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
20103010 Biotechnology
Products and services
01 Sep 2021
18:25 CEST
GENSIGHT BIOLOGICS
GENSIGHT BIOLOGICS : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
01 Sep 2021
17:45 CEST
GENSIGHT BIOLOGICS
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September
20103010 Biotechnology
Other subject
01 Sep 2021
17:45 CEST
GENSIGHT BIOLOGICS
Les résultats cliniques des thérapies géniques LUMEVOQ®et GS030 de GenSight Biologics seront présentés au congrès 2021 de l’ISGEDR ainsi qu’à plusieurs conférences Investisseurs en septembre
20103010 Biotechnology
Other subject
31 Aug 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce la publication des donnéesde l’étude RESTORE démontrantl’efficacité prolongée de LUMEVOQ®3 ans après injection unilatérale
20103010 Biotechnology
Other subject
31 Aug 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
20103010 Biotechnology
Other subject
29 Jul 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics publie ses résultats financiers du premier semestre 2021 et fait un point sur ses activités
20103010 Biotechnology
Other subject
29 Jul 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update
20103010 Biotechnology
Other subject
05 Jul 2021
18:43 CEST
GENSIGHT BIOLOGICS
GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
20103010 Biotechnology
Other subject
05 Jul 2021
18:43 CEST
GENSIGHT BIOLOGICS
GenSight Biologics tiendra des webcasts avec des leaders d’opinion sur les résultats de l’étude clinique de Phase III REFLECT de LUMEVOQ®
20103010 Biotechnology
Other subject
05 Jul 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics annonce l’octroi d’une Autorisation Temporaire d’Utilisation de Cohorte (ATUc) pour LUMEVOQ® en France
20103010 Biotechnology
Other subject
05 Jul 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
20103010 Biotechnology
Other subject
30 Jun 2021
07:30 CEST
GENSIGHT BIOLOGICS
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva